| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner | 2025-10-17 | 32,217 | $7.84 | $252.58kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-16 | 150,000 | $8.86 | $1.33MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-15 | 51,500 | $7.94 | $409.06kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-14 | 15,032 | $7.59 | $114.05kBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-10 | 277,298 | $7.36 | $2.04MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-09 | 626,043 | $6.70 | $4.19MBuy |
| Lynx1 Capital Management LP | 10% Owner | 2025-10-08 | 556,300 | $6.46 | $3.59MBuy |
| Jacquelyn L. Sumer | Chief Legal Officer | 2025-02-25 | 3,756 | $8.53 | $32.04kSell |
| Nadim Ahmed | President and CEO | 2025-02-25 | 12,529 | $8.53 | $106.87kSell |
| Jeffrey Alan Jones | Chief Medical Officer | 2025-02-25 | 4,895 | $8.53 | $41.75kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ansbert Gadicke | 27.38% | 16,157,644 | $125.38M | Insider |
| Lynx1 Capital Management LP | 14.91% | 8,797,833 | $68.27M | Insider |
| Ubs Oncology Impact Fund LP | 12.96% | 7,648,268 | $59.35M | Insider |
| Mpm Bioimpact LLC | 12.96% | 7,648,268 | $59.35M | Institution |
| Bvf Inc | 9.74% | 5,750,683 | $44.63M | Institution |
| Morana Jovanembiricos | 7.85% | 4,631,022 | $35.94M | Insider |
| Vision Scs F2 | 7.59% | 4,476,350 | $34.74M | Insider |
| F2 Bioscience I 2017 Ltd | 7.51% | 4,430,964 | $34.38M | Insider |
| Lynx1 Capital Management LP | 7.46% | 4,400,842 | $34.15M | Institution |
| Blackrock Inc | 7.15% | 4,217,933 | $32.73M | Institution |